secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-265800
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma Q3 net loss widens to $72M; EMA accepts MAAs for obicetrapib
--------------------------------------------------------------------------------

- Cash, equivalents and securities $756M as of Sep 30, 2025, down from $834.2M at Dec 31, 2024.
- Net loss $72.0M in Q3 2025 vs $16.6M loss in Q3 2024; revenue fell to $0.3M from $29.1M.
- European Medicines Agency accepted MAAs for obicetrapib monotherapy and FDC with ezetimibe.
- R&D expenses $31.0M (down 13% YoY); SG&A $24.5M (up 33% YoY), driven by personnel and share-based compensation.
- Ongoing Phase 3 trials: PREVAIL CVOT (>9,500 enrolled), REMBRANDT plaque imaging, and RUBENS (diabetes) expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312525265800/0001193125-25-265800-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312525265800/nams-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-265800

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer